SHIN-ETSU-CHEMICAL
12.6.2024 06:01:28 CEST | Business Wire | Press release
Shin-Etsu Chemical Co., Ltd. (TOKYO: 4063) (Head Office: Tokyo; President: Yasuhiko Saitoh; hereinafter, “Shin-Etsu Chemical”) has developed equipment to manufacture semiconductor package substrates with a new manufacturing method subsequently to manufacturing micro-LED manufacturing system. The equipment is a high-performance processing equipment using excimer laser in which a dual damascene method, as is also used in the front end of semiconductor manufacturing process, is applied to package substrate manufacturing process (back end process) (Shin-Etsu dual damascene method). As a result, an interposer’s functions directly formed into a package substrate. This not only eliminates the need of an interposer, but also enables further microfabrication, where conventional manufacturing methods could not realize. It also reduces costs and capital investment as it does not require the photoresist process in package substrate manufacturing process.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240611403511/en/
Two-layer sample processed by Shin-Etsu dual damascene method (Cross-section view) (Photo: Business Wire)
A chiplet, in which circuits are singulated and then assembled in a package, has caught attention as a technology to reduce the manufacturing cost of higher-performance semiconductors. This technology requires a process to mount several chiplets on an intermediate substrate and connect them. The intermediate substrate is called an “interposer.”
With the Shin-Etsu dual damascene method, interposer is not necessary any more, so it significantly simplifies the assembly process. In this method, chiplets are connected to a package substrate with wiring patterns which has equivalent function to an interposer. Consequently, the assembly process of advanced semiconductors with chiplet technology can be shortened and its cost can be drastically reduced.
The equipment’s sophisticated microfabrication technology allows complicated electric circuit patterns to be formed directly in each organic insulation layers of a multi-layered package substrate, followed by circuit forming by copper plating. It uses an excimer laser as a light source to form large-area electric circuit patterns in batches. The Shin-Etsu dual damascene method enables further miniaturized microfabrication, which could not be achieved by semi-additive processing (SAP) method using dry film resist, as is current mainstream. The laser processing equipment can process an area of 100 mm square or larger at one time with a combination of a photomask made of Shin-Etsu’s large photomask blanks and its unique special lens. Processing time varies depending on the size of one package substrate, but the time required to process the wiring pattern and electrode pads is the same as the time required to process vias. Moreover, the via processing time does not depend on the number of vias. For example, it takes about 20 minutes to form trenches of 2 µm width and 5 µm depth and electrode pads of 10 µm diameter and 5 µm depth on an organic substrate of 515 mm × 510 mm, as well as to form vias (upper diameter 7 µm, lower diameter 5 µm, depth 5 µm).
Shin-Etsu Chemical is working on initiatives to integrate its own material and equipment technologies. By developing new process technology, we will propose total solutions from the perspectives of both equipment and materials and take the lead in the development of next-generation technologies to create an affluent society.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240611403511/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
